ReviewCell & bioscience2023
Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions.
Review in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 31 citations in OpenAlex.
- Circulating tumor cells predict early skeletal-related events in patients with bone metastases from breast cancer.The journal of liquid biopsy · 2026Article
- Phylogeography of Bone Metastasis: Clonal Evolution, Skeletal Niche Adaptation, and Clinical Implications.International journal of molecular sciences · 2026Review
- Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities.Biomolecules · 2026Review
- Succinate drives breast cancer bone metastasis by activating the HIF1α/YTHDF1/YAP signaling axis to upregulate chemokine CXCL5 and disrupt the bone microenvironment.Apoptosis : an international journal on programmed cell death · 2026Article
- A pH-responsive layered double hydroxide nanoradiosensitizer for bone metastasis tumor.Materials today. Bio · 2026Article
- Review
- TFRC promotes ferroptosis to suppress breast cancer bone metastasis via the activation of HIF-1 pathway.Breast cancer research : BCR · 2026Article
- The Osteoblastic Microenvironment Determines the Fate of Breast Cancer Cells Disseminated in the Bone Marrow.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Independent Risk Factors and a New Nomogram for Predicting Breast Cancer Risk for Bone Metastasis in Chinese Women: A Retrospective Study with External Validation.Journal of clinical medicine · 2026Article
- Review
- Migrasome and cancer - from cellular to clinical perspectives.Biomarker research · 2026Review
- Development and validation of an interpretable machine learning-based predictive model for breast cancer bone metastasis.Frontiers in oncology · 2026Article
- Targeting Netrin-1 Mediates the Suppression of Osteolytic Bone Metastasis in Breast Cancer by Ugonin L.International journal of biological sciences · 2026Article
- Robust Association of Breast Cancer Co-morbidity Using Subtype-specific Expressed Genes.Current drug targets · 2026Article
- miR-202-5p mitigates the advancement of osteoporosis through the regulation of PTEN.Journal of orthopaedic surgery and research · 2025Article
- TransBreastNet a CNN transformer hybrid deep learning framework for breast cancer subtype classification and temporal lesion progression analysis.Scientific reports · 2025Article
- Relationship Between Urinary 6-Sulfatoxymelatonin Rhythms and the Bone Resorption Marker Amino-Terminal Cross-Linked Telopeptide of Collagen I in Blind Women.Journal of pineal research · 2025Article
- Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.Biomedicines · 2025Review
- Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors.Biomarker research · 2025Review
- Development of a novel risk signature revealing prognostic and tumor microenvironmental features in breast cancer.Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The most common site of metastasis in breast cancer is the bone, where the balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation is disrupted. This imbalance causes osteolytic bone metastasis in breast cancer, which leads to bone pain, pathological fractures, spinal cord compression, and other skeletal-related events (SREs). These complications reduce patients' quality of life significantly and have a profound impact on prognosis. In this review, we begin by providing a brief overview of the epidemiology of bone metastasis in breast cancer, including current diagnostic tools, treatment approaches, and existing challenges. Then, we will introduce the pathophysiology of breast cancer bone metastasis (BCBM) and the animal models involved in the study of BCBM. We then come to the focus of this paper: a discussion of several biomarkers that have the potential to provide predictive and prognostic value in the context of BCBM-some of which may be particularly compatible with more comprehensive liquid biopsies. Beyond that, we briefly explore the potential of new technologies such as single-cell sequencing and organoid models, which will improve our understanding of tumor heterogeneity and aid in the development of improved biomarkers. The emerging biomarkers discussed hold promise for future clinical application, aiding in the prevention of BCBM, improving the prognosis of patients, and guiding the implementation of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.